Le Lézard
Classified in: Health
Subjects: PDT, AVO

FARE Launches Baby's First: Reduce the Risk of Food Allergies


MCLEAN, Va., April 30, 2020 /PRNewswire/ -- Today, FARE (Food Allergy Research & Education), the world's leading food allergy advocacy organization and the largest private funder of food allergy research, announced the launch of a new resource geared at raising awareness of the benefits of introducing a variety of new foods to babies and educating people on how they might be able to help reduce the risk of developing food allergies.

"Food allergies affect 5.6 million children. The incidence of food allergies is increasing every day, and has doubled over the last decade," said Lisa Gable, chief executive officer of FARE. "Parents want their babies to get the best nutrition but it's not easy to know how exactly to go about that, especially given the abundance of information available to parents online. FARE created Baby's First so new and soon-to-be parents have access to all the best information on introducing new foods, available in one place from a trusted source."

Dr. Ruchi Gupta will serve as lead spokesperson for Baby's First. Dr. Gupta is a Professor of Pediatrics and Medicine at Northwestern University, Clinical Attending at Lurie Children's Hospital of Chicago, and a mother to two children, one of whom has severe food allergies. Gupta also serves as FARE's Medical Advisor for Policy, Education and Public Health.

"For a long time, parents and doctors alike believed babies should not be exposed to certain foods in their first year but things have changed," said Dr. Gupta. "Strong research and promising studies now show that introducing a variety of foods into a baby's diet is recommended ?and it may help lower the risk of certain food allergies like peanuts.  Of course, always discuss with your baby's doctor first.  I am thrilled to be playing a part in FARE's efforts to raise awareness around this important topic and look forward to helping parents all over the country as they embark on this new adventure."

Published in 2015 and funded in part by FARE, the Learning Early About Peanut Allergy (LEAP) study transformed the guidance that pediatricians and allergists/immunologists give to parents about when to introduce peanut foods to children. The research led the American Academy of Pediatrics to endorse early introduction of peanut foods for infants at risk for peanut allergy. In 2017, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, published new guidelines for introducing peanut foods to infants. These recommendations vary depending on a baby's risk of developing peanut allergy, which can be evaluated by the baby's primary care physician or by an allergist/immunologist. Baby's First brings together the latest expert advice to help guide how parents and families can put these recommendations into practice.

For more information on early introduction and Baby's First, visit www.BabysFirst.org.

About FARE
FARE (Food Allergy Research & Education) is the world's leading food allergy advocacy organization and the largest private funder of food allergy research. Our mission is to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments. For more information, please visit www.foodallergy.org.

SOURCE FARE (Food Allergy Research & Education)


These press releases may also interest you

at 08:16
On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) successfully issued senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years (the "Bonds"). Pursuant to the terms and...

at 08:07
On the evening of May 5, Kexing Biopharm (stock code: 688136) announced it had obtained a "Certificate of GMP Compliance of a Manufacturer" granted by the Norwegian Medical Products Agency in accordance with the European Medicines Agency (EMA)...

at 08:05
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET. The presentation will...

at 08:05
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 10,...

at 08:05
Viridian Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming...

at 08:05
$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results in the wind down of the PUR1900 Phase 2b study and allows for a significant...



News published on and distributed by: